THZ1 is a potent and covalent inhibitor of CDK7 with an IC50 of 3.2 nM. It also inhibits the CDK12 and CDK13 and downregulates MYC expression. It exhibits strong anti proliferative effect across a broad range of cancer cell lines including human T-cell acute lymphoblastic leukaemia (T-ALL) cancer.